Stock Analysis

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

  •  Updated
Source: Shutterstock

We'd be surprised if Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shareholders haven't noticed that the President, Vincent Milano, recently sold US$161k worth of stock at US$4.32 per share. That sale was 20% of their holding, so it does make us raise an eyebrow.

See our latest analysis for Idera Pharmaceuticals

The Last 12 Months Of Insider Transactions At Idera Pharmaceuticals

Notably, that recent sale by Vincent Milano is the biggest insider sale of Idera Pharmaceuticals shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$4.26. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

In the last year Idera Pharmaceuticals insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqCM:IDRA Insider Trading Volume December 27th 2020

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Idera Pharmaceuticals insiders own 1.7% of the company, worth about US$2.6m. However, it's possible that insiders might have an indirect interest through a more complex structure. We consider this fairly low insider ownership.

So What Does This Data Suggest About Idera Pharmaceuticals Insiders?

An insider sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we're not rushing to buy, to say the least. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To that end, you should learn about the 4 warning signs we've spotted with Idera Pharmaceuticals (including 1 which is potentially serious).

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you decide to trade Idera Pharmaceuticals, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

What are the risks and opportunities for Aceragen?

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.

View Full Analysis


  • Highly volatile share price over the past 3 months

  • Makes less than USD$1m in revenue ($49K)

  • Shareholders have been substantially diluted in the past year

  • Does not have a meaningful market cap ($49M)

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report